On April 14, 2020, Velan Capital, L.P., Altiva Management Inc., Balaji Venkataraman, and Deepak Sarpangal entered into an agreement with Progenics Pharmaceuticals, Inc., pursuant to which the Company agreed to pay the Velan Capital stockholders $1,300,000 as partial reimbursement for their expenses incurred in connection with the Velan stockholders’ involvement with the Company, including their successful consent solicitation in 2019 to reconstitute the Company’s Board of Directors. Also on April 14, 2020, Velan Capital stated that it has entered into a support agreement with Lantheus Holdings, Inc., pursuant to which, among other things, Velan Capital agreed to (i) vote or cause to be voted its respective shares of common stock of the Company in favor of adoption and approval of the Merger Agreement, and (ii) vote or cause to be voted its respective shares of common stock of Lantheus Holdings in favor of the issuance of common stock of Lantheus Holdings in connection with the transactions contemplated by the Merger Agreement.